Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Zantrene
Zantrene® is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Over-production of the FTO protein has been found to be an important factor in the growth of a diverse range of cancers. Race Oncology is exploring the use of Zantrene as a new therapy for Acute Myeloid Leukaemia (AML), melanoma and clear cell renal cell carcinoma (kidney cancer), which are all frequent FTO-driven cancers.
The Company has compelling clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers and is investigating its use in these areas.
Recent studies by Race have identified Zantrene is able to protect the heart muscle from anthracycline-induced damage while being able to synergise to better treat the cancer.
Race is pursuing outsized commercial returns for its shareholders via the ‘Three Pillar’ strategy.
We recently presented our updated strategic plans for Race Oncology at our 2021 Annual General Meeting.
Race is led by a seasoned team and Board, supported by a network of key opinion leaders and collaborators. See our leadership team here.